Compare VMET & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VMET | SVRA |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | Canada | United States |
| Employees | 8 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | N/A | 2009 |
| Metric | VMET | SVRA |
|---|---|---|
| Price | $12.64 | $5.29 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | 209.2K | ★ 1.2M |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $185.47 | N/A |
| Revenue Next Year | $16.05 | $430.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.10 | $1.89 |
| 52 Week High | $13.73 | $7.01 |
| Indicator | VMET | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 56.95 | 45.63 |
| Support Level | $11.00 | $4.95 |
| Resistance Level | $13.73 | $6.15 |
| Average True Range (ATR) | 0.68 | 0.29 |
| MACD | 0.12 | -0.07 |
| Stochastic Oscillator | 58.97 | 27.72 |
Versamet Royalties Corp is a diversified metals royalty and streaming company with exposure to a range of resource royalties and streams including gold, silver, copper, zinc, graphite and uranium, across a variety of jurisdictions. The Company's operating segments are considered to be its individual royalties, streams and the Greenstone gold interest.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).